Jeffrey Vorsanger, MD
Pulmonary Disease · Brooklyn, NYNPI 1306829429
Payments from drug & device makers
What this record shows
This record is dominated by education: $11,333 of the $11,375 with a category attached, or 99.6%. Angiodynamics, Inc. accounts for 99.6% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2021 at $10,000 and has fallen 99.8% since, to $16 in 2025.
Across 4 payments — averaging $2843.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$11K
- Abbott$25
- Amgen$16
What the payments were for
- Food & beverage$410%
- Education$11,333100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 2 | $11,333 |
| Abbott | 1 | $25 |
| Amgen | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auryon Laser System 100-120 Vac$10,000
- Auryon$1,333
How this compares
$11,375 in reported general payments places this provider in the 85th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 119 | $130,365 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 83 | $66,648 |
| JanuviaSitagliptin Phosphate | 49 | $60,482 |
| JardianceEmpagliflozin | 46 | $46,903 |
| MounjaroTirzepatide | 35 | $46,204 |
| FarxigaDapagliflozin Propanediol | 29 | $37,287 |
| OzempicSemaglutide | 16 | $32,856 |
| XareltoRivaroxaban | 16 | $18,086 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $16,415 |
| MyrbetriqMirabegron | 14 | $16,394 |
| SynthroidLevothyroxine Sodium | 200 | $13,929 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 20 | $11,081 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $10,441 |
| Atorvastatin Calcium | 593 | $9,215 |
| Rosuvastatin Calcium | 365 | $7,292 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Brooklyn
- Ali El AtatBrooklyn$482K
- Sunil MehraBrooklyn$388K
- Xiaojun YanBrooklyn$249K
- Boris SagalovichBrooklyn$212K
- Chaim BernsteinBrooklyn$186K
- Jeffrey WolfGreat Neck$892K
- Keith HarrisPort Jefferson Station$832K
- Jack MannBayside$736K
- Raji AyinlaBronx$673K
- Charles PowellNew York$654K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.